SAN FRANCISCO, CA--(Marketwire - December 17, 2012) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced that its Board of Directors has elected N. Anthony Coles, M.D., Chairman of the Board. Dr. Coles is currently President, Chief Executive Officer and a member of Onyx's Board. Paul Goddard, Ph.D., will continue to serve as Lead Independent Director of the Onyx Board.
"On behalf of the Board of Directors, I would like to congratulate Tony on this well-deserved appointment," said Dr. Goddard. "Through his steadfast, focused leadership, Onyx has grown exponentially, transforming from a company with one therapy to a diversified biopharmaceutical leader with three approved treatments to address some of the most difficult-to-treat cancers."
"Paul's leadership has been instrumental in our ability to realize Onyx's growth and transformation," said Dr. Coles. "I look forward to continuing our successful partnership as Onyx moves into this next stage as a global, multi-product company."
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.